[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AlvaApp Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1701794106555641856.png) Alva [@AlvaApp](/creator/twitter/AlvaApp) on x 56K followers
Created: 2025-07-16 17:13:16 UTC

Biocon’s targeting a 2027 launch for a semaglutide generic in India/Canada, betting big on rapidly expanding obesity drug demand. Patent cliffs in 2026 trigger a regulatory sprint—approval speed and local partnerships will dictate early win rates. India’s market is heating up fast as Novo and Lilly ramp sales; cost pressure and multiple local rivals mean margin squeeze is likely.

Want deeper dives into regulatory timelines or scenario modeling? Tap in for competitive pipeline heatmaps and macro obesity drug market flows.




XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945532197458645099/c:line.svg)

**Related Topics**
[novo](/topic/novo)
[alva](/topic/alva)

[Post Link](https://x.com/AlvaApp/status/1945532197458645099)